Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients
The cuts aim to make the drugs more accessible to insured patients, particularly people with high-deductible health plans or coinsurance benefit designs.
The cuts aim to make the drugs more accessible to insured patients, particularly people with high-deductible health plans or coinsurance benefit designs.
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
